bioMérieux (OTCMKTS:BMXMF) Lifted to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of bioMérieux (OTCMKTS:BMXMFGet Rating) from a sell rating to a hold rating in a report issued on Tuesday morning, reports.

According to Zacks, “bioMérieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioMérieux S.A. is based in Marcy L Etoile, France. “

OTCMKTS:BMXMF opened at $91.50 on Tuesday. bioMérieux has a 12 month low of $87.13 and a 12 month high of $148.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.31 and a quick ratio of 1.65. The company’s 50 day moving average is $101.10 and its 200-day moving average is $116.27.

About bioMérieux (Get Rating)

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors.

Further Reading

Get a free copy of the Zacks research report on bioMérieux (BMXMF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for bioMérieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioMérieux and related companies with's FREE daily email newsletter.